Alumis (ALMS) to Release Earnings on Wednesday

Alumis (NASDAQ:ALMS) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Alumis to post earnings of ($0.90) per share and revenue of $2.75 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Alumis Trading Up 4.7%

Shares of NASDAQ ALMS opened at $28.10 on Wednesday. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -6.94 and a beta of -2.15. Alumis has a 12-month low of $2.76 and a 12-month high of $30.60. The stock’s 50 day simple moving average is $24.52 and its 200 day simple moving average is $12.68.

Insiders Place Their Bets

In other news, major shareholder Foresite Capital Management Vi bought 411,764 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the transaction, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. The trade was a 7.78% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James B. Tananbaum acquired 411,764 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the director directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. The trade was a 7.78% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 1,823,527 shares of company stock worth $30,999,959. 40.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alumis

Several large investors have recently bought and sold shares of the business. MPM Bioimpact LLC acquired a new stake in Alumis during the 4th quarter worth $23,443,000. Orbimed Advisors LLC bought a new position in shares of Alumis in the 2nd quarter worth $5,779,000. Woodline Partners LP grew its stake in shares of Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after purchasing an additional 1,558,660 shares during the period. Samsara Biocapital LLC grew its holdings in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Alumis by 263.1% in the fourth quarter. Millennium Management LLC now owns 1,151,118 shares of the company’s stock worth $11,235,000 after acquiring an additional 834,089 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Chardan Capital started coverage on Alumis in a research note on Wednesday, January 21st. They issued a “buy” rating and a $37.00 price objective on the stock. Morgan Stanley raised their price objective on shares of Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Alumis in a research note on Tuesday, January 6th. Citigroup reaffirmed an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Finally, UBS Group restated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.